Equities

MBX Biosciences Inc

MBX:NSQ

MBX Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)22.55
  • Today's Change1.32 / 6.22%
  • Shares traded438.20k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. It has built its proprietary Precision Endocrine Peptide platform to develop precision peptide therapies that are designed to overcome key limitations of current peptide therapies. Its product candidates and programs include MBX 2109, MBX 1416 and Obesity portfolio. MBX 2109 is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. MBX 1416 is designed to be a long-acting glucagon-like peptide-1 (GLP-1), receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. MBX 4291 is designed to be a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide, receptor co-agonist prodrug.

  • Revenue in USD (TTM)0.00
  • Net income in USD-47.20m
  • Incorporated2019
  • Employees36.00
  • Location
    MBX Biosciences Inc11711 N. Meridian Street, Suite 300CARMEL 46032United StatesUSA
  • Phone+1 (317) 659-0200
  • Fax+1 (302) 655-5049
  • Websitehttps://mbxbio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Adaptive Biotechnologies Corp168.77m-213.47m685.75m709.00--2.84--4.06-1.47-1.471.161.640.25014.745.03238,033.80-31.65-19.69-36.63-22.0654.7767.18-126.55-122.273.84--0.3536---8.1125.06-12.52--11.11--
Ironwood Pharmaceuticals, Inc.400.57m9.21m686.88m267.0099.51--74.491.710.04320.04322.43-2.010.8021--4.521,500,244.001.44-4.542.21-5.20----1.79-7.81--4.602.07--7.835.02-672.50--160.10--
Wave Life Sciences Ltd110.50m-73.74m708.51m266.00------6.41-0.5796-0.57960.92750.03590.5036----415,413.50-33.49-56.98-117.16-102.38-----66.50-353.20----0.00--3,005.1051.0464.46---35.44--
ProKidney Corp0.00-38.68m712.60m163.00---------0.5905-0.59050.00-7.730.00----0.00-27.97------------------0.0003------67.17------
Astria Therapeutics Inc0.00-93.24m713.78m59.00--2.76-----2.30-2.300.006.320.00----0.00-32.43-64.48-33.78-68.34------------0.00-------40.62------
MBX Biosciences Inc0.00-47.20m718.30m36.00---------1.48-1.480.001.71------0.00--------------------0.00-------24.60------
Stoke Therapeutics Inc15.16m-103.57m723.91m110.00--2.96--47.76-2.18-2.180.3174.640.0537--68.74137,790.90-36.68-31.62-41.57-33.92-----683.31-1,775.50----0.00---29.22---3.59--11.56--
Savara Inc0.00-75.29m739.06m37.00--6.10-----0.4317-0.43170.000.73610.00----0.00-58.02-36.86-62.14-39.54-------102,587.50----0.2066-------43.38--15.91--
Annexon Inc0.00-115.16m742.75m71.00--2.05-----1.22-1.220.003.420.00----0.00-36.04-44.06-38.13-46.93------------0.00------5.43--62.56--
Replimune Group Inc0.00-220.01m745.39m331.00--1.75-----3.27-3.270.006.240.00----0.00-38.64-29.08-41.09-30.56------------0.143-------23.82--16.84--
Scholar Rock Holding Corp0.00-203.85m751.51m150.00--5.62-----2.22-2.220.001.670.00----0.00-79.66-38.14-89.70-44.31-------647.95----0.2726---100.00---23.26---45.61--
Zenas Biopharma Inc50.00m-54.76m756.06m114.00------15.12-1.38-1.381.264.04------595,238.10-------------109.51------0.00------68.88------
Arbutus Biopharma Corp10.06m-77.09m758.90m73.00--6.20--75.43-0.4416-0.44160.05750.64880.0597--4.59137,821.90-45.77-52.62-53.21-58.11-----766.20-537.81----0.00---53.5125.00-4.89---2.40--
AbCellera Biologics Inc33.06m-153.30m763.18m586.00--0.6870--23.09-0.5254-0.52540.11333.770.0224--0.80856,407.85-10.396.08-11.116.67-----463.7724.69----0.000.00-92.1733.91-192.35--70.96--
Rapport Therapeutics Inc-100.00bn-100.00bn776.52m58.00--2.30----------9.21----------------------------0.00-------226.57------
Data as of Sep 20 2024. Currency figures normalised to MBX Biosciences Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.